Fig. 5

Effect of hG-CSF gene therapy on the IRE1 and PERK and ATF6 pathway. a, b Western blot analysis of IREI and its downstream player, in the frontal and middle brain sections of sham, AAV-CMV-GFP and AAV-CMV-hG-CSF treated mice at a 4- and b 7-days post-BCAO (n = 6 animals/group). c, d Western blot analysis of the downstream player in the PERK pathway, ATF4, in the frontal and middle brain sections of sham, AAV-CMV-GFP and AAV-CMV-hG-CSF treated mice at c 4- and d 7- days post-BCAO and e, f western blot analysis of cleaved ATF6 e 4- and f 7-days post-BCAO. Statistical analysis was performed by One Way ANOVA, with Tukey as post hoc test and expressed as means ± S.E.M; *p < 0.05/**p < 0.01/***p < 0.001 versus Sham group while ^#p < 0.05/^##p < 0.01/^###p < 0.001 versus AAV-CMV-GFP- treated group. (n = 7 animals/group)